US FDA delays on biosimilar approvals
Rituximab BLA received a CRL; abatacept and semaglutide approvals face regulatory uncertainty.
DRREDDY / Q2-FY26 / risks
Keep the risk register visible.
Dr. Reddy's Laboratories · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Revlimid revenue decline
Revlimid sales are declining faster than expected, with Q3 likely the last quarter of meaningful contribution.
Semaglutide Canada pricing and competition
Multiple filers and potential compounding pharmacy entry could lead to aggressive pricing and lower margins.
Patent litigation outcome in India for semaglutide
Awaiting Delhi High Court decision; adverse ruling could delay India launch and impact export plans.